Login to Your Account



Other News To Note


Wednesday, May 16, 2012
• BioAlliance Pharma SA, of Paris, said it started its Phase III ReLive trial testing Livatag (doxorubicin Transdrug) in nearly 400 patients with hepatocellular carcinoma, who are resistant or intolerant to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription